贝伐珠单抗联合XELOX化疗方案治疗老年结肠癌患者的效果

Effects of Bevacizumab combined with XELOX chemotherapy regimen in treatment of elderly patients with colon cancer

目的:观察贝伐珠单抗联合XELOX化疗方案治疗老年结肠癌患者的效果。方法:选取2022年12月至2023年12月该院收治的68例老年结肠癌患者进行前瞻性研究,按随机数字表法将其分为对照组与研究组各34例。对照组采用XELOX化疗方案治疗,研究组在对照组基础上联合贝伐珠单抗治疗,比较两组临床疗效,治疗前后肿瘤标志物[糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、糖类抗原125(CA125)]、血管内皮功能指标[血管内皮生长因子(VEGF)、环氧化酶-2(COX-2)、基质金属蛋白酶-9(MMP-9)]水平,以及不良反应发生率。结果:研究组疾病缓解率、疾病控制率均高于对照组,差异有统计学意义(P<0.05);治疗后,两组CA19-9、CEA、CA125水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组VEGF、COX-2、MMP-9水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:贝伐珠单抗联合XELOX化疗方案治疗老年结肠癌患者可提高疾病缓解率和疾病控制率,降低肿瘤标志物和血管内皮功能指标水平,其效果优于单纯XELOX化疗方案治疗。

Objective:To observe effects of Bevacizumab combined with XELOX chemotherapy regimen in treatment of elderly patients with colon cancer.Methods:A prospective study was conducted on 68 elderly patients with colon cancer admitted to this hospital from December 2022 to December 2023.According to the random number table method,they were divided into control group and study group,34 cases in each group.The control group was treated with XELOX chemotherapy regimen,while the study group was treated with Bevacizumab on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[carbohydrate antigen 199(CA19-9),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)]and vascular endothelial function indexes[vascular endothelial growth factor(VEGF),cyclooxygenase-2(COX-2),matrix metalloproteinase-9(MMP-9)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease remission rate and the disease control rate of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CA19-9,CEA and CA125 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of VEGF,COX-2 and MMP-9 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bevacizumab combined with XELOX chemotherapy in the treatment of the elderly patients with colon cancer can improve the disease remission rate and the disease control rate,and reduce the levels of tumor markers and vascular endothelial function indexes.Moreover,it is superior to simple XELOX chemotherapy.